Fusion Pharmaceuticals Inc.
FUSNDelisted Jun 5, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001805890
Fusion Pharmaceuticals Inc. was delisted on Jun 5, 2024; its insiders filed their last Form 4 on Jun 4, 2024; 114 institutions reported holding it in 13F filings for Q1 2024, worth $1.47B in total; Duquesne Family Office was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Fusion Pharmaceuticals Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Fusion Pharmaceuticals Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Cagnoni Pablo J | Director | – | Jun 4, 2024 | 0 |
| Duncan Barbara Gayle | Director | – | Jun 4, 2024 | 0 |
| Leamon Christopher P | Chief Scientific Officer | 0 | Jun 4, 2024 | 0 |
| Meek David D. | Director | – | Jun 4, 2024 | 0 |
| Crowley John J | Chief Financial Officer | 0 | Jun 4, 2024 | 0 |
| Gannon Steven | Director | 0 | Jun 4, 2024 | 0 |
| Bergstrom Donald A | Director | – | Jun 4, 2024 | 0 |
| Valliant John | Chief Executive Officer | 0 | Jun 4, 2024 | 0 |
| Burak Eric | Chief Technology Officer | 0 | Jun 4, 2024 | 0 |
| Lee Philina | Director | – | Jun 4, 2024 | 0 |
| Bender Jeremy | Director | – | Jun 4, 2024 | 0 |
| Rawat Mohit | President & CBO | 0 | Jun 4, 2024 | 0 |
| Bobilev Dmitri | Chief Medical Officer | – | Jun 4, 2024 | 0 |
| Bitetti Teresa Marie | Director | – | Jun 4, 2024 | 0 |
| Preston Heather | Director | – | Jun 14, 2023 | 0 |
| Khuong Chau Quang | Director | 42,093 | Jun 14, 2023 | 0 |
| O'Leary James J | Chief Medical Officer | 2,022 | Feb 3, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2022 (view filing) | Aug 11 | Same day | Gannon StevenDirector | PPurchase | +44.4K | $2.03 | +$90.1K | +370.0%56.4K after | |
| Apr 27, 2022 (view filing) | Apr 25-27 | 2 days | Valliant JohnChief Executive Officer | SSale | −8.69K | $6.04 | −$52.5K | −2.7%318.1K after | 3 lots |
| Apr 22, 2022 (view filing) | Apr 20-21 | 2 days | Valliant JohnChief Executive Officer | SSale | −1.29K | $6.01 | −$7.75K | −0.4%326.8K after | 2 lots |
| Apr 13, 2022 (view filing) | Apr 11-13 | 2 days | Valliant JohnChief Executive Officer | SSale | −32.8K | $6.87 | −$225.7K | −9.1%328.1K after | 3 lots |
| Apr 8, 2022 (view filing) | Apr 6-8 | 2 days | Valliant JohnChief Executive Officer | SSale | −2.18K | $7.55 | −$16.5K | −0.6%361.0K after | 3 lots |
| Apr 5, 2022 (view filing) | Apr 1-5 | 4 days | Valliant JohnChief Executive Officer | SSale | −3.80K | $7.72 | −$29.3K | −1.0%363.2K after | 3 lots |
| Apr 1, 2022 (view filing) | Mar 30 | 2 days | Valliant JohnChief Executive Officer | SSale | −300 | $7.52 | −$2.26K | −0.1%367.0K after | |
| Mar 29, 2022 (view filing) | Mar 25-29 | 4 days | Valliant JohnChief Executive Officer | SSale | −10.3K | $7.54 | −$77.7K | −2.7%367.3K after | 3 lots |
| Mar 24, 2022 (view filing) | Mar 21-23 | 3 daysLate | Valliant JohnChief Executive Officer | SSale | −4.80K | $7.52 | −$36.1K | −1.3%377.6K after | 3 lots |
| Mar 21, 2022 (view filing) | Mar 17-21 | 4 days | Valliant JohnChief Executive Officer | SSale | −3.60K | $7.53 | −$27.1K | −0.9%382.4K after | 3 lots |
| Mar 16, 2022 (view filing) | Mar 14-16 | 2 days | Valliant JohnChief Executive Officer | SSale | −1.50K | $6.97 | −$10.5K | −0.4%386.0K after | 3 lots |
| Mar 14, 2022 (view filing) | Mar 9-11 | 5 daysLate | Valliant JohnChief Executive Officer | SSale | −2.82K | $7.03 | −$19.8K | −0.7%387.5K after | 3 lots |
| Mar 8, 2022 (view filing) | Mar 4-8 | 4 days | Valliant JohnChief Executive Officer | SSale | −14.5K | $7.17 | −$103.9K | −3.6%390.3K after | 3 lots |
| Mar 3, 2022 (view filing) | Mar 1-3 | 2 days | Valliant JohnChief Executive Officer | SSale | −27.6K | $7.44 | −$205.2K | −6.4%404.8K after | 3 lots |
| Feb 28, 2022 (view filing) | Feb 24-28 | 4 days | Valliant JohnChief Executive Officer | SSale | −13.8K | $7.50 | −$103.2K | −3.1%432.4K after | 3 lots |
| Feb 23, 2022 (view filing) | Feb 18-23 | 5 days | Valliant JohnChief Executive Officer | SSale | −38.3K | $7.79 | −$298.4K | −7.9%446.1K after | 3 lots |
| Feb 17, 2022 (view filing) | Feb 15-17 | 2 days | Valliant JohnChief Executive Officer | SSale | −47.5K | $8.08 | −$383.8K | −8.9%484.4K after | 3 lots |
| Aug 23, 2021 (view filing) | Aug 23 | Same day | Gannon StevenDirector | PPurchase | +2.83K | $7.99 | +$22.6K | +30.8%12.0K after | |
| Aug 20, 2021 (view filing) | Aug 18-19 | 2 days | Gannon StevenDirector | PPurchase | +3.17K | $8.05 | +$25.5K | +52.8%9.17K after | 2 lots |
| Aug 17, 2021 (view filing) | Aug 16 | 1 day | Gannon StevenDirector | PPurchase | +6.00K | $8.10 | +$48.6K | New position6.00K after |